avVaa World Health Care Products, Inc. Announces Engagement of Koeppel Direct
for their DRTV-Direct Response Television Media Buying Campaign
LUMBY, BC, July 2 /PRNewswire-FirstCall/ - avVaa World Health Care Products
Inc. (Pink Sheets: AVVH), a global biotechnology company, manufacturer and
distributor of nationally branded therapeutic, natural skin and health care
products, announced the engagement of Koeppel Direct to manage their direct
response media buying.
Lorie Campbell-Farley, President/COO of avVaa World Health Care is excited to
be associated with Koeppel Direct, a world-class direct response television
media buying agency, specializing in Multi-Channel Direct Response Television
- DRTV online direct response, radio direct response and print direct response
campaign management. Koeppel Direct has a reputation for generating increased
results, immediately and over the long-term.
Loren Wayne of Koeppel Direct states his firm is leading the charge to provide
clients in the direct response industry with an integrated, multi-channel
response media buying strategy. "We will integrate all the key mediums that
comprise an effective direct response media buy, including-direct response
television (DRTV), online, print, and radio to ensure the success of the avVaa
World Health Care direct response media campaign".
Ms Farley, states, "it's a wonderful feeling that Koeppel Direct knows the ins
and outs of maximizing the impact of a direct response television advertizing
campaign. The caliber of Koeppel Direct's direct response media buying
performance is why marketers depend on their expertise campaign after
campaign."
avVaa World Health Care will receive DRTV media buying results that are
measurable specific and immediate.
About avVaa World Health Care Products
avVaa World Health Care Products is a global biotechnology company that
specializes in effective, all natural, therapeutic skin care products that
improve quality of life and well being for consumers. avVaa's patented
European skin care formulas are scientifically registered, FDA-Compliant, and
were developed to relieve and treat the symptoms of common skin ailments,
including eczema, psoriasis and acne. avVaa is poised to manufacture and
market its OTC Neuroskin(r) line of skin care products through mass, food and
drug channels in the United States and globally. The Company's secondary line
of equine and pet care related products are already being distributed
throughout all of Canada. For more information, visit: www.avvaa.com.
Safe Harbor: Statements contained in this press release that are not based
upon current or historical fact are forward looking in nature. Such
forward-looking statements are subject to risks and uncertainties, which could
cause actual results to differ materially from estimated results. Management
cautions that all statements as to future results of operations are
necessarily subject to risks, uncertainties, and events that may be beyond the
control of avVaa World Health Care Products, Inc. and no assurance can be
given that such results will be achieved.
Potential risks and uncertainties include but are not limited to the ability
to procure, properly price, retain, and successfully complete projects, the
availability of technical personnel, changes in technology, and competition.
SOURCE avVaa World Health Care Products
avVaa World Health Care Products, Jack Farley, Chairman, CEO,
jfarley@avvaa.com; Lorie Campbell-Farley, President, COO, lcfarley@avvaa.com;
Investor Relations: Merle Goertz (West Coast), (604) 688-2349
